HRP20131021T1 - Novi 7-deazapurin nukleozidi za terapijske uporabe - Google Patents

Novi 7-deazapurin nukleozidi za terapijske uporabe Download PDF

Info

Publication number
HRP20131021T1
HRP20131021T1 HRP20131021AT HRP20131021T HRP20131021T1 HR P20131021 T1 HRP20131021 T1 HR P20131021T1 HR P20131021A T HRP20131021A T HR P20131021AT HR P20131021 T HRP20131021 T HR P20131021T HR P20131021 T1 HRP20131021 T1 HR P20131021T1
Authority
HR
Croatia
Prior art keywords
compound according
pharmaceutically acceptable
hydrogen
mixture
acceptable salt
Prior art date
Application number
HRP20131021AT
Other languages
English (en)
Croatian (hr)
Inventor
Aurelie Bourderioux
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. filed Critical Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.
Publication of HRP20131021T1 publication Critical patent/HRP20131021T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20131021AT 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe HRP20131021T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Publications (1)

Publication Number Publication Date
HRP20131021T1 true HRP20131021T1 (hr) 2014-01-31

Family

ID=42768153

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131021AT HRP20131021T1 (hr) 2009-04-22 2010-04-19 Novi 7-deazapurin nukleozidi za terapijske uporabe

Country Status (15)

Country Link
US (3) US9321800B2 (enExample)
EP (1) EP2421879B1 (enExample)
JP (2) JP5721275B2 (enExample)
CN (2) CN104497084B (enExample)
AU (3) AU2010238985B2 (enExample)
CA (2) CA2759131C (enExample)
DK (1) DK2421879T3 (enExample)
ES (1) ES2437917T3 (enExample)
HR (1) HRP20131021T1 (enExample)
MX (1) MX2011011160A (enExample)
NZ (2) NZ596301A (enExample)
PL (1) PL2421879T3 (enExample)
PT (1) PT2421879E (enExample)
SI (1) SI2421879T1 (enExample)
WO (1) WO2010121576A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド
EA201270661A1 (ru) * 2009-12-18 2013-06-28 Президент Энд Феллоуз Оф Гарвард Колледж УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
US10414788B2 (en) 2016-06-29 2019-09-17 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US11072628B2 (en) 2017-10-19 2021-07-27 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en) * 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
MX2021015772A (es) * 2019-06-18 2022-01-31 Taiho Pharmaceutical Co Ltd Compuesto de carbonato novedoso que tiene esqueleto de pirrolopirimidina o sal farmaceuticamente aceptable del mismo.
US20230104311A1 (en) * 2020-02-17 2023-04-06 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
CA3233416A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
US7157434B2 (en) * 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
WO2006033709A2 (en) * 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
TR201815961T4 (tr) * 2008-01-18 2018-11-21 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Yeni sitostatik 7-deazapürin nükleozidleri.
BRPI0914626A2 (pt) * 2008-06-23 2015-10-20 Janssen Pharmaceutica Nv antagonistas de piperidil acrilamida de ccr2
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド

Also Published As

Publication number Publication date
JP2015013901A (ja) 2015-01-22
CN104497084A (zh) 2015-04-08
CA2966647A1 (en) 2010-10-28
AU2015205885B2 (en) 2017-04-06
JP2012524731A (ja) 2012-10-18
AU2010238985A1 (en) 2011-12-01
US10294262B2 (en) 2019-05-21
US20170240584A1 (en) 2017-08-24
ES2437917T3 (es) 2014-01-15
US20150218201A1 (en) 2015-08-06
PL2421879T3 (pl) 2014-02-28
WO2010121576A3 (en) 2011-06-16
CN104497084B (zh) 2018-06-05
NZ596301A (en) 2014-10-31
US20160318970A1 (en) 2016-11-03
US9624257B2 (en) 2017-04-18
CA2759131C (en) 2017-06-20
SI2421879T1 (sl) 2014-01-31
AU2017204148B2 (en) 2018-12-06
US9321800B2 (en) 2016-04-26
JP6087889B2 (ja) 2017-03-01
MX2011011160A (es) 2012-01-27
AU2017204148A1 (en) 2017-07-06
JP5721275B2 (ja) 2015-05-20
CN102459300A (zh) 2012-05-16
CA2759131A1 (en) 2010-10-28
PT2421879E (pt) 2013-12-09
AU2015205885A1 (en) 2015-09-03
DK2421879T3 (da) 2013-11-25
HK1166325A1 (en) 2012-12-14
AU2010238985B2 (en) 2015-04-23
CN102459300B (zh) 2014-12-10
EP2421879A2 (en) 2012-02-29
EP2421879B1 (en) 2013-09-04
WO2010121576A2 (en) 2010-10-28
NZ700583A (en) 2016-04-29
HK1209129A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
HRP20131021T1 (hr) Novi 7-deazapurin nukleozidi za terapijske uporabe
HRP20171957T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka
JP2009514870A5 (enExample)
JP2017528524A5 (enExample)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
ME02638B (me) Inhibitori replikacije virusa gripa
AR106252A2 (es) Compuestos de pirrolo[2,3-d]pirimidina
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
HRP20201727T1 (hr) 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora
BR112015023705A8 (pt) compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
GT201300137A (es) Derivados de imidazo [1,2-b] piridazina e imidazo [4,5-b] piridina como inhibidores de jak
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
DOP2010000387A (es) Compuestos pirazolicos 436
UA115320C2 (uk) Інгібітори кінази
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
JP2016532667A5 (enExample)
HRP20161344T1 (hr) Novi citostatski 7-deazapurinski nukleozidi
JP2015512943A5 (enExample)
HRP20150030T1 (hr) Derivati pirazolokinolina kao inhibitori dna-pk
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
RU2014107484A (ru) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas